Bioengineering
-
KAIST develops technology for selective RNA modification in living cells and animals
· A team led by Professor Won Do Heo from the Department of Biological Sciences, KAIST, has developed a pioneering technology that selectively acetylates specific RNA molecules in living cells and tissues.
· The platform uses RNA-targeting CRISPR tools in combination with RNA-modifying enzymes to chemically modify only the intended RNA.
· The method opens new possibilities for gene therapy by enabling precise control of disease-related RNA without affecting the rest of the transcriptome.
< Photo 1. (From left) Professor Won Do Heo and Jihwan Yu, a Ph.D. Candidate of the Department of Biological Sciences >
CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects. Utilizing this system, researchers at KAIST have now developed the world’s first technology capable of selectively acetylating (chemically modifying) specific RNA molecules among countless transcripts within living cells. This breakthrough enables precise, programmable control of RNA function and is expected to open new avenues in RNA-based therapeutic development.
KAIST (President Kwang Hyung Lee) announced that a research team led by Professor Won Do Heo in the Department of Biological Sciences has recently developed a groundbreaking technology capable of selectively acetylating specific RNA molecules within the human body using the CRISPR-Cas13 system—an RNA-targeting platform gaining increasing attention in the fields of gene regulation and RNA-based therapeutics.
RNA molecules can undergo chemical modifications—the addition of specific chemical groups—which alter their function and behavior without changing the underlying nucleotide sequence. However, some of these modifications, a critical layer of post-transcriptional gene regulation, remain poorly understood. Among them, N4-acetylcytidine (ac4C) has been particularly enigmatic, with ongoing debate about its existence and function in human messenger RNA (mRNA), the RNA that encodes proteins.
To address this gap, the KAIST research team developed a targeted RNA acetylation system, named dCas13-eNAT10. This platform combines a catalytically inactive Cas13 enzyme (dCas13) that guides the system to specific RNA targets, with a hyperactive variant of the NAT10 enzyme (eNAT10), which performs RNA acetylation. This approach enables precise acetylation of only the desired RNA molecules among the vast pool of transcripts within the cell.
< Figure 1. Development of hyperactive variant eNAT10 through NAT10 protein engineering. By engineering the NAT10 protein, which performs RNA acetylation in human cells, based on its domain and structure, eNAT10 was developed, showing approximately a 3-fold increase in RNA acetylation activity compared to the wild-type enzyme. >
Using this system, the researchers demonstrated that guide RNAs could direct the dCas13-eNAT10 complex to acetylate specific RNA targets, and acetylation significantly increased protein expression from the modified mRNA. Moreover, the study revealed, for the first time, that RNA acetylation plays a role in intracellular RNA localization, facilitating the export of RNA from the nucleus to the cytoplasm—a critical step in gene expression regulation.
To validate its therapeutic potential, the team successfully delivered the targeted RNA acetylation system into the livers of live mice using adeno-associated virus (AAV), a commonly used gene therapy vector. This marks the first demonstration of in vivo RNA modification, extending the applicability of RNA chemical modification tools from cell culture models to living organisms.
< Figure 2. Acetylation of various RNA in cells using dCas13-eNAT10 fusion protein. Utilizing the CRISPR-Cas13 system, which can precisely target specific RNA through guide RNA, a dCas13-eNAT10 fusion protein was created, demonstrating its ability to specifically acetylate various endogenous RNA at different locations within cells. >
Professor Won Do Heo, who previously developed COVID-19 treatment technology using RNA gene scissors and technology to activate RNA gene scissors with light, stated, "Existing RNA chemical modification research faced difficulties in controlling specificity, temporality, and spatiality. However, this new technology allows selective acetylation of desired RNA, opening the door for accurate and detailed research into the functions of RNA acetylation." He added, "The RNA chemical modification technology developed in this study can be widely used as an RNA-based therapeutic agent and a tool for regulating RNA functions in living organisms in the future."
< Figure 3. In vivo delivery of targeted RNA acetylation system. The targeted RNA acetylation system was encoded in an AAV vector, commonly used in gene therapy, and delivered intravenously to adult mice, showing that target RNA in liver tissue was specifically acetylated according to the guide RNA. >
This research, with Ph.D. candidate Jihwan Yu from the Department of Biological Sciences at KAIST as the first author, was published in the journal Nature Chemical Biology on June 2, 2025. (Title: Programmable RNA acetylation with CRISPR-Cas13, Impact factor: 12.9, DOI: https://doi.org/10.1038/s41589-025-01922-3)
This research was supported by the Samsung Future Technology Foundation and the Bio & Medical Technology Development Program of the National Research Foundation of Korea.
2025.06.10 View 307 -
A 10-Month Journey of Tiny Flaps Completed: A Special Family Returns to KAIST Duck Pond
On the morning of June 9, 2025, gentle activity stirred early around the KAIST campus duck pond. It was the day a special family of ducks—and two goslings—were to be released back into the pond after spending a month in a temporary shelter. One by one, the ducklings cautiously emerged from their box, waddling toward the water's edge and scanning their surroundings, followed closely by their mother.
< The landscape manager from the KAIST Facilities Team releases the ducks and goslings. >
The mother duck, once a rescued loner who couldn’t integrate with the flock, returned triumphantly as the head of a new family—caring for both ducklings and goslings. Students and faculty looked on quietly, welcoming them back and reflecting on their remarkable 10-month journey.
The story began in July 2024, as a student filed a report of spotting two ducklings wandering near the pond without a mother. Based on their soft down, flat beaks, and lack of fear around humans, it was presumed they had been abandoned. Professor Won Do Heo of the Department of Biological Sciences—affectionately known as the “Goose Dad”—and the KAIST Facilities Team quickly stepped in to rescue them. After about a month of care, the ducklings were released back into the pond.
< On June 9, the day of the release, KAIST President Kwang-Hyung Lee (left), the former “Goose Dad,” and Professor Won Do Heo (right), the current “Goose Dad,” watched the flock as they freely wobbled about. >
At first, the ducklings seemed to adapt, but they started distancing themselves from the established goose flock. One eventually disappeared, and the remaining duckling was found injured by the pond during winter. Although KAIST typically avoids making human interference in the natural ecosystem, an exception was made to save the young duck’s life. It was put under the care of Professor Heo and the Facilities Team to regain its health within a month.
In the spring, the healed duck began laying eggs. Professor Heo supported the process by adjusting its diet, avoiding further intervention. On Children’s Day, May 5, the duck’s eggs hatched. The once-isolated duck had become a mother. Ten days later, on May 15, four goslings also hatched from the resident goose flock. With new life flourishing, the pond was more vibrant than ever.
< Rescued baby goslings near the pond, alongside the duck family that took them in. The mother duck—once a vulnerable duckling herself—had grown strong enough to care for others in need. >
But just days later, the mother goose disappeared, and two goslings—still unable to swim—were found shivering by the pond. Dahyeon Byeon, a student from Seoul National University who came for a visit on that day, reported this upon sighting, prompting another rescue. The vulnerable goslings were brought to the shelter to stay with the duck family.
Initially, the interspecies cohabitation was uneasy. But the mother duck did not reject the goslings. Slowly, they began to eat and sleep together, forming a new kind of family. After a month, they were released together into the pond—and to everyone’s surprise, the existing goose flock accepted both the goslings and the duck family.
< A peaceful moment for the duck family. The baby goslings naturally followed the mother duck. >
It took ten months for this family to return. From abandonment and injury to healing, birth, and unexpected bonds, this was more than a story of survival. It was a journey of transformation. The duck family’s ten-month saga is a quiet miracle—written in small moments of crisis, care, and connection—and a lasting memory on the KAIST campus.
< The resident goose flock at KAIST’s pond naturally accepted the returning duck and goslings as part of their group. >
2025.06.10 View 373 -
KAIST-UIUC researchers develop a treatment platform to disable the ‘biofilm’ shield of superbugs
< (From left) Ph.D. Candidate Joo Hun Lee (co-author), Professor Hyunjoon Kong (co-corresponding author) and Postdoctoral Researcher Yujin Ahn (co-first author) from the Department of Chemical and Biomolecular Engineering of the University of Illinois at Urbana-Champaign and Ju Yeon Chung (co-first author) from the Integrated Master's and Doctoral Program, and Professor Hyun Jung Chung (co-corresponding author) from the Department of Biological Sciences of KAIST >
A major cause of hospital-acquired infections, the super bacteria Methicillin-resistant Staphylococcus aureus (MRSA), not only exhibits strong resistance to existing antibiotics but also forms a dense biofilm that blocks the effects of external treatments. To meet this challenge, KAIST researchers, in collaboration with an international team, successfully developed a platform that utilizes microbubbles to deliver gene-targeted nanoparticles capable of break ing down the biofilms, offering an innovative solution for treating infections resistant to conventional antibiotics.
KAIST (represented by President Kwang Hyung Lee) announced on May 29 that a research team led by Professor Hyun Jung Chung from the Department of Biological Sciences, in collaboration with Professor Hyunjoon Kong's team at the University of Illinois, has developed a microbubble-based nano-gene delivery platform (BTN MB) that precisely delivers gene suppressors into bacteria to effectively remove biofilms formed by MRSA.
The research team first designed short DNA oligonucleotides that simultaneously suppress three major MRSA genes, related to—biofilm formation (icaA), cell division (ftsZ), and antibiotic resistance (mecA)—and engineered nanoparticles (BTN) to effectively deliver them into the bacteria.
< Figure 1. Effective biofilm treatment using biofilm-targeting nanoparticles controlled by microbubbler system. Schematic illustration of BTN delivery with microbubbles (MB), enabling effective permeation of ASOs targeting bacterial genes within biofilms infecting skin wounds. Gene silencing of targets involved in biofilm formation, bacterial proliferation, and antibiotic resistance leads to effective biofilm removal and antibacterial efficacy in vivo. >
In addition, microbubbles (MB) were used to increase the permeability of the microbial membrane, specifically the biofilm formed by MRSA. By combining these two technologies, the team implemented a dual-strike strategy that fundamentally blocks bacterial growth and prevents resistance acquisition.
This treatment system operates in two stages. First, the MBs induce pressure changes within the bacterial biofilm, allowing the BTNs to penetrate. Then, the BTNs slip through the gaps in the biofilm and enter the bacteria, delivering the gene suppressors precisely. This leads to gene regulation within MRSA, simultaneously blocking biofilm regeneration, cell proliferation, and antibiotic resistance expression.
In experiments conducted in a porcine skin model and a mouse wound model infected with MRSA biofilm, the BTN MB treatment group showed a significant reduction in biofilm thickness, as well as remarkable decreases in bacterial count and inflammatory responses.
< Figure 2. (a) Schematic illustration on the evaluation of treatment efficacy of BTN-MB gene therapy. (b) Reduction in MRSA biofilm mass via simultaneous inhibition of multiple genes. (c, d) Antibacterial efficacy of BTN-MB over time in a porcine skin infection biofilm model. (e) Schematic of the experimental setup to verify antibacterial efficacy in a mouse skin wound infection model. (f) Wound healing effects in mice. (g) Antibacterial effects at the wound site. (h) Histological analysis results. >
These results are difficult to achieve with conventional antibiotic monotherapy and demonstrate the potential for treating a wide range of resistant bacterial infections.
Professor Hyun Jung Chung of KAIST, who led the research, stated, “This study presents a new therapeutic solution that combines nanotechnology, gene suppression, and physical delivery strategies to address superbug infections that existing antibiotics cannot resolve. We will continue our research with the aim of expanding its application to systemic infections and various other infectious diseases.”
< (From left) Ju Yeon Chung from the Integrated Master's and Doctoral Program, and Professor Hyun Jung Chung from the Department of Biological Sciences >
The study was co-first authored by Ju Yeon Chung, a graduate student in the Department of Biological Sciences at KAIST, and Dr. Yujin Ahn from the University of Illinois. The study was published online on May 19 in the journal, Advanced Functional Materials.
※ Paper Title: Microbubble-Controlled Delivery of Biofilm-Targeting Nanoparticles to Treat MRSA Infection ※ DOI: https://doi.org/10.1002/adfm.202508291
This study was supported by the National Research Foundation and the Ministry of Health and Welfare, Republic of Korea; and the National Science Foundation and National Institutes of Health, USA.
2025.05.29 View 388 -
Decoding Fear: KAIST Identifies An Affective Brain Circuit Crucial for Fear Memory Formation by Non-nociceptive Threat Stimulus
Fear memories can form in the brain following exposure to threatening situations such as natural disasters, accidents, or violence. When these memories become excessive or distorted, they can lead to severe mental health disorders, including post-traumatic stress disorder (PTSD), anxiety disorders, and depression. However, the mechanisms underlying fear memory formation triggered by affective pain rather than direct physical pain have remained largely unexplored – until now.
A KAIST research team has identified, for the first time, a brain circuit specifically responsible for forming fear memories in the absence of physical pain, marking a significant advance in understanding how psychological distress is processed and drives fear memory formation in the brain. This discovery opens the door to the development of targeted treatments for trauma-related conditions by addressing the underlying neural pathways.
< Photo 1. (from left) Professor Jin-Hee Han, Dr. Junho Han and Ph.D. Candidate Boin Suh of the Department of Biological Sciences >
KAIST (President Kwang-Hyung Lee) announced on May 15th that the research team led by Professor Jin-Hee Han in the Department of Biological Sciences has identified the pIC-PBN circuit*, a key neural pathway involved in forming fear memories triggered by psychological threats in the absence of sensory pain. This groundbreaking work was conducted through experiments with mice.*pIC–PBN circuit: A newly identified descending neural pathway from the posterior insular cortex (pIC) to the parabrachial nucleus (PBN), specialized for transmitting psychological threat information.
Traditionally, the lateral parabrachial nucleus (PBN) has been recognized as a critical part of the ascending pain pathway, receiving pain signals from the spinal cord. However, this study reveals a previously unknown role for the PBN in processing fear induced by non-painful psychological stimuli, fundamentally changing our understanding of its function in the brain.
This work is considered the first experimental evidence that 'emotional distress' and 'physical pain' are processed through different neural circuits to form fear memories, making it a significant contribution to the field of neuroscience. It clearly demonstrates the existence of a dedicated pathway (pIC-PBN) for transmitting emotional distress.
The study's first author, Dr. Junho Han, shared the personal motivation behind this research: “Our dog, Lego, is afraid of motorcycles. He never actually crashed into one, but ever since having a traumatizing event of having a motorbike almost run into him, just hearing the sound now triggers a fearful response. Humans react similarly – even if you didn’t have a personal experience of being involved in an accident, a near-miss or exposure to alarming media can create lasting fear memories, which may eventually lead to PTSD.”
He continued, “Until now, fear memory research has mainly relied on experimental models involving physical pain. However, much of real-world human fears arise from psychological threats, rather than from direct physical harm. Despite this, little was known about the brain circuits responsible for processing these psychological threats that can drive fear memory formation.”
To investigate this, the research team developed a novel fear conditioning model that utilizes visual threat stimuli instead of electrical shocks. In this model, mice were exposed to a rapidly expanding visual disk on a ceiling screen, simulating the threat of an approaching predator. This approach allowed the team to demonstrate that fear memories can form in response to a non-nociceptive, psychological threat alone, without the need for physical pain.
< Figure 1. Artificial activation of the posterior insular cortex (pIC) to lateral parabrachial nucleus (PBN) neural circuit induces anxiety-like behaviors and fear memory formation in mice. >
Using advanced chemogenetic and optogenetic techniques, the team precisely controlled neuronal activity, revealing that the lateral parabrachial nucleus (PBN) is essential to form fear memories in response to visual threats. They further traced the origin of these signals to the posterior insular cortex (pIC), a region known to process negative emotions and pain, confirming a direct connection between the two areas.
The study also showed that inhibiting the pIC–PBN circuit significantly reduced fear memory formation in response to visual threats, without affecting innate fear responses or physical pain-based learning. Conversely, artificially activating this circuit alone was sufficient to drive fear memory formation, confirming its role as a key pathway for processing psychological threat information.
< Figure 2. Schematic diagram of brain neural circuits transmitting emotional & physical pain threat signals. Visual threat stimuli do not involve physical pain but can create an anxious state and form fear memory through the affective pain signaling pathway. >
Professor Jin-Hee Han commented, “This study lays an important foundation for understanding how emotional distress-based mental disorders, such as PTSD, panic disorder, and anxiety disorder, develop, and opens new possibilities for targeted treatment approaches.”
The findings, authored by Dr. Junho Han (first author), Ph.D. candidate Boin Suh (second author), and Dr. Jin-Hee Han (corresponding author) of the Department of Biological Sciences, were published online in the international journal Science Advances on May 9, 2025.※ Paper Title: A top-down insular cortex circuit crucial for non-nociceptive fear learning. Science Advances (https://doi.org/10.1101/2024.10.14.618356)※ Author Information: Junho Han (first author), Boin Suh (second author), and Jin-Hee Han (corresponding author)
This research was supported by grants from the National Research Foundation of Korea (NRF-2022M3E5E8081183 and NRF-2017M3C7A1031322).
2025.05.15 View 1662 -
Editing Parkinson's Disease – KAIST Makes World's First Discovery of an Inflammatory RNA Editing Enzyme through Co-work with UCL Researchers
< Professor Minee Choi of the Department of Brain and Cognitive Sciences (top left). Professor Sonia Gandhi (top right) and Professor Klenerman of the University College London (bottom right) >
Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein protein abnormally aggregates within brain cells, causing neuronal damage. Through international collaboration, researchers at KAIST have revealed that RNA editing plays a crucial role in regulating neuroinflammation, a key pathology of Parkinson's disease.
KAIST (represented by President Kwang-Hyung Lee) announced on the 27th of April that a research team led by Professor Minee L. Choi from the Department of Brain and Cognitive Sciences, in collaboration with University College London (UCL) and the Francis Crick Institute, discovered that the RNA editing enzyme ADAR1 plays an important role in controlling immune responses in astrocytes, glial cells that trigger protective reactions in the brain, and demonstrated that this mechanism is critically involved in the progression of Parkinson’s disease.
Professor Choi's research team created a co-culture model composed of astrocytes and neurons derived from stem cells originating from Parkinson's disease patients, in order to study the inflammatory responses of brain immune cells. They then treated the model with α-synuclein aggregates, which are known to cause Parkinson’s disease, and analyzed how the immune cells' inflammatory responses changed.
< Figure 1. Schematic diagram of the inflammatory RNA editing model in Parkinson's disease >
As a result, it was found that early pathological forms of α-synuclein, known as oligomers, activated the Toll-like receptor pathway, which acts as a danger sensor in astrocytes, as well as the interferon response pathway, an immune signaling network that combats viruses and pathogens. During this process, the RNA editing enzyme ADAR1 was expressed and transformed into an isoform with an altered protein structure and function.
Notably, the RNA editing activity of ADAR1, which normally functions to regulate immune responses during viral infections by converting adenosine (A) to inosine (I) through a process known as A-to-I RNA editing, was found to be abnormally focused on genes that cause inflammation rather than operating under normal conditions. This phenomenon was observed not only in the patient-derived neuron models but also in postmortem brain tissues from actual Parkinson’s disease patients.
< Figure 2. Experimental design and inflammatory response induction in astrocytes following treatment with α-synuclein oligomers (abnormally folded protein fragments) >
This directly proves that the dysregulation of RNA editing induces chronic inflammatory responses in astrocytes, ultimately leading to neuronal toxicity and pathological progression.
This study is significant in that it newly identified the regulation of RNA editing within astrocytes as a key mechanism behind neuroinflammatory responses. In particular, it suggests that ADAR1 could serve as a novel genetic target for the treatment of Parkinson’s disease.
It is also noteworthy that the study reflected actual pathological characteristics of patients by utilizing patient-specific induced pluripotent stem cell-based precision models for brain diseases.
Professor Minee L. Choi stated, “This study demonstrates that the regulator of inflammation caused by protein aggregation operates at the new layer of RNA editing, offering a completely different therapeutic strategy from existing approaches to Parkinson's disease treatment." She further emphasized, “RNA editing technology could become an important turning point in the development of therapeutics for neuroinflammation.”
< Figure 3. When treated with α-synuclein oligomers, the causative agent of Parkinson's disease, A-to-I RNA editing is induced to change genetic information by ADAR in patient-derived stem cell-differentiated glial cells, confirming that α-synuclein is likely to be associated with the progression of Parkinson's disease through RNA editing >
This study was published in Science Advances on April 11, with Professor Choi listed as a co-first author.
Paper Title: Astrocytic RNA editing regulates the host immune response to alpha-synuclein, Science Advances Vol.11, Issue 15. (DOI:10.1126/sciadv.adp8504)
Lead Authors: Karishma D’Sa (UCL, Co-First Author), Minee L. Choi (KAIST, Co-First Author), Mina Ryten (UCL, Corresponding Author), Sonia Gandhi (Francis Crick Institute, University of Cambridge, Corresponding Author)
This research was supported by the Brain Research Program and the Excellent Young Researcher Program of the National Research Foundation of Korea, as well as KAIST’s Daekyo Cognitive Enhancement Program.
2025.05.02 View 2687 -
Formosa Group of Taiwan to Establish Bio R&D Center at KAIST Investing 12.5 M USD
KAIST (President Kwang-Hyung Lee) announced on February 17th that it signed an agreement for cooperation in the bio-medical field with Formosa Group, one of the three largest companies in Taiwan.
< Formosa Group Chairman Sandy Wang and KAIST President Kwang-Hyung Lee at the signing ceremony >
Formosa Group Executive Committee member and Chairman Sandy Wang, who leads the group's bio and eco-friendly energy sectors, decided to establish a bio-medical research center within KAIST and invest approximately KRW 18 billion or more over 5 years. In addition, to commercialize the research results, KAIST and Formosa Group will establish a joint venture in Korea with KAIST Holdings, a KAIST-funded company.
The cooperation between the two organizations began in early 2023 when KAIST signed a comprehensive exchange and cooperation agreement (MOU) with Ming Chi University of Science and Technology (明志科技大學), Chang Gung University (長庚大學), and Chang Gung Memorial Hospital (長庚記念醫院), which are established and supported by Formosa Group. Afterwards, Chairman Sandy Wang visited KAIST in May 2024 and signed a more specific business agreement (MOA).
KAIST Holdings is a holding company established by KAIST, a government-funded organization, to attract investment and conduct business, and will pursue the establishment of a joint venture with a 50:50 equity structure in cooperation with Formosa Group. KAIST Holdings will invest KAIST’s intellectual property rights, and Formosa Group will invest a corresponding amount of funds.
The KAIST-Formosa joint venture will provide research funds to the KAIST-Formosa Bio-Medical Research Center to be established in the future, secure the right to implement the intellectual property rights generated, and promote full-scale business.
The KAIST-Formosa Bio-Medical Research Center will establish a ‘brain organoid bank’ created by obtaining tissues from hundreds of patients with degenerative brain diseases, thereby securing high-dimensional data that will reveal the fundamental causes of aging and disease. It is expected that KAIST’s world-class artificial intelligence technology will analyze large-scale patient data to find the causes of aging and disease.
Through this business, it is expected that by 2030, five years from now, it will discover more than 10 types of intractable brain disease treatments and expand to more than 20 businesses, including human cell-centered diagnostics and preclinical businesses, and secure infrastructure and intellectual property rights that can create value worth approximately KRW 250 billion.
The Chang Gung Memorial Hospital in Taiwan has 10,000 beds and handles 35,000 patients per day, and systematically accumulates patient tissue and clinical data. Chang Gung Memorial Hospital will differentiate the tissues of patients with degenerative brain diseases and send them to the KAIST-Formosa Bio-Medical Research Center, which will then produce brain organoids to be used for disease research and new drug development. This will allow the world’s largest patient tissue data bank to be established.
Dean Daesoo Kim of the College of Life Science and Bioengineering at KAIST said, “This collaboration between KAIST and Formosa Group is a new research collaboration model that goes beyond joint research to establish a joint venture and global commercialization of developed technologies, and it is significant in that it can serve as an opportunity to promote biomedical research and development.”
With this agreement, KAIST, which has been promoting the KAIST Advanced Regenerative Medicine Engineering Center in Osong K-Bio Square, has secured a practical global partner.
< Representatives of the Formosa Group and KAIST >
KAIST’s Senior Vice President for Planning and Budget, Professor Kyung-Soo Kim emphasized, “KAIST has made great efforts to secure an edge in state-of-the-art biomedical fields such as stem cells and gene editing technology, by attracting the world’s best experts and discovering global cooperation partners, and these results can ultimately be linked to the Osong K-Bio Square project.”
SVP Kim then predicted, “In particular, the practical cooperation with Taiwan’s best Formosa Chang Gung Memorial Hospital, which has abundant clinical experience in stem cell treatment, will be an important axis of KAIST’s bio innovation strategy.”
Formosa Chairman Sandy Wang emphasized that this investment and cooperation is built on trust in KAIST’s R&D capabilities and the passion of its researchers. And added that through this, the Formosa Group will practice corporate social responsibility and take an important first step together with KAIST to protect the welfare and health of humanity. She also went on the say that she expects to see the cooperation expanded to various fields such as mobility and semiconductors based on the successes begotten from the cooperation in the bio field.
KAIST President Kwang-Hyung Lee said, “I evaluate this agreement as one of the most important events that will spearhead KAIST into overseas biotechnology stages,” and added, “I expect that this cooperation will be an opportunity for Taiwan and Korea, both of which have IT industry-centered structures, to create new growth engines in the bio industry.” Meanwhile, Formosa Group is a company founded by Chairman Sandy Wang’s father, Chairman Yung-Ching Wang. It is the world’s No. 1 plastic PVC producer and is leading core industries of the Taiwanese economy, including semiconductors, steel, heavy industry, bio, and batteries. Chairman Yung-Ching Wang was respected by the Taiwanese people for his exemplary return of wealth to society under the belief that the companies and assets he founded “belong to the people.”
2025.02.17 View 3022 -
KAIST Uncovers the Principles of Gene Expression Regulation in Cancer and Cellular Functions
< (From left) Professor Seyun Kim, Professor Gwangrog Lee, Dr. Hyoungjoon Ahn, Dr. Jeongmin Yu, Professor Won-Ki Cho, and (below) PhD candidate Kwangmin Ryu of the Department of Biological Sciences>
A research team at KAIST has identified the core gene expression networks regulated by key proteins that fundamentally drive phenomena such as cancer development, metastasis, tissue differentiation from stem cells, and neural activation processes. This discovery lays the foundation for developing innovative therapeutic technologies.
On the 22nd of January, KAIST (represented by President Kwang Hyung Lee) announced that the joint research team led by Professors Seyun Kim, Gwangrog Lee, and Won-Ki Cho from the Department of Biological Sciences had uncovered essential mechanisms controlling gene expression in animal cells.
Inositol phosphate metabolites produced by inositol metabolism enzymes serve as vital secondary messengers in eukaryotic cell signaling systems and are broadly implicated in cancer, obesity, diabetes, and neurological disorders.
The research team demonstrated that the inositol polyphosphate multikinase (IPMK) enzyme, a key player in the inositol metabolism system, acts as a critical transcriptional activator within the core gene expression networks of animal cells. Notably, although IPMK was previously reported to play an important role in the transcription process governed by serum response factor (SRF), a representative transcription factor in animal cells, the precise mechanism of its action was unclear.
SRF is a transcription factor directly controlling the expression of at least 200–300 genes, regulating cell growth, proliferation, apoptosis, and motility, and is indispensable for organ development, such as in the heart.
The team discovered that IPMK binds directly to SRF, altering the three-dimensional structure of the SRF protein. This interaction facilitates the transcriptional activity of various genes through the SRF activated by IPMK, demonstrating that IPMK acts as a critical regulatory switch to enhance SRF's protein activity.
< Figure 1. The serum response factor (SRF) protein, a key transcription factor in animal cells, directly binds to inositol polyphosphate multikinase (IPMK) enzyme and undergoes structural change to acquire DNA binding ability, and precisely regulates growth and differentiation of animal cells through transcriptional activation. >
The team further verified that disruptions in the direct interaction between IPMK and SRF lead to the reduced functionality and activity of SRF, causing severe impairments in gene expression.
By highlighting the significance of the intrinsically disordered region (IDR) in SRF, the researchers underscored the biological importance of intrinsically disordered proteins (IDPs). Unlike most proteins that adopt distinct structures through folding, IDPs, including those with IDRs, do not exhibit specific structures but play crucial biological roles, attracting significant attention in the scientific community.
Professor Seyun Kim commented, "This study provides a vital mechanism proving that IPMK, a key enzyme in the inositol metabolism system, is a major transcriptional activator in the core gene expression network of animal cells. By understanding fundamental processes such as cancer development and metastasis, tissue differentiation from stem cells, and neural activation through SRF, we hope this discovery will lead to the broad application of innovative therapeutic technologies."
The findings were published on January 7th in the international journal Nucleic Acids Research (IF=16.7, top 1.8% in Biochemistry and Molecular Biology), under the title “Single-molecule analysis reveals that IPMK enhances the DNA-binding activity of the transcription factor SRF" (DOI: 10.1093/nar/gkae1281).
This research was supported by the National Research Foundation of Korea's Mid-career Research Program, Leading Research Center Program, and Global Research Laboratory Program, as well as by the Suh Kyungbae Science Foundation and the Samsung Future Technology Development Program.
2025.01.24 View 8602 -
A Way for Smartwatches to Detect Depression Risks Devised by KAIST and U of Michigan Researchers
- A international joint research team of KAIST and the University of Michigan developed a digital biomarker for predicting symptoms of depression based on data collected by smartwatches
- It has the potential to be used as a medical technology to replace the economically burdensome fMRI measurement test
- It is expected to expand the scope of digital health data analysis
The CORONA virus pandemic also brought about a pandemic of mental illness. Approximately one billion people worldwide suffer from various psychiatric conditions. Korea is one of more serious cases, with approximately 1.8 million patients exhibiting depression and anxiety disorders, and the total number of patients with clinical mental diseases has increased by 37% in five years to approximately 4.65 million. A joint research team from Korea and the US has developed a technology that uses biometric data collected through wearable devices to predict tomorrow's mood and, further, to predict the possibility of developing symptoms of depression.
< Figure 1. Schematic diagram of the research results. Based on the biometric data collected by a smartwatch, a mathematical algorithm that solves the inverse problem to estimate the brain's circadian phase and sleep stages has been developed. This algorithm can estimate the degrees of circadian disruption, and these estimates can be used as the digital biomarkers to predict depression risks. >
KAIST (President Kwang Hyung Lee) announced on the 15th of January that the research team under Professor Dae Wook Kim from the Department of Brain and Cognitive Sciences and the team under Professor Daniel B. Forger from the Department of Mathematics at the University of Michigan in the United States have developed a technology to predict symptoms of depression such as sleep disorders, depression, loss of appetite, overeating, and decreased concentration in shift workers from the activity and heart rate data collected from smartwatches.
According to WHO, a promising new treatment direction for mental illness focuses on the sleep and circadian timekeeping system located in the hypothalamus of the brain, which directly affect impulsivity, emotional responses, decision-making, and overall mood.
However, in order to measure endogenous circadian rhythms and sleep states, blood or saliva must be drawn every 30 minutes throughout the night to measure changes in the concentration of the melatonin hormone in our bodies and polysomnography (PSG) must be performed. As such treatments requires hospitalization and most psychiatric patients only visit for outpatient treatment, there has been no significant progress in developing treatment methods that take these two factors into account. In addition, the cost of the PSG test, which is approximately $1000, leaves mental health treatment considering sleep and circadian rhythms out of reach for the socially disadvantaged.
The solution to overcome these problems is to employ wearable devices for the easier collection of biometric data such as heart rate, body temperature, and activity level in real time without spatial constraints. However, current wearable devices have the limitation of providing only indirect information on biomarkers required by medical staff, such as the phase of the circadian clock.
The joint research team developed a filtering technology that accurately estimates the phase of the circadian clock, which changes daily, such as heart rate and activity time series data collected from a smartwatch. This is an implementation of a digital twin that precisely describes the circadian rhythm in the brain, and it can be used to estimate circadian rhythm disruption.
< Figure 2. The suprachiasmatic nucleus located in the hypothalamus of the brain is the central biological clock that regulates the 24-hour physiological rhythm and plays a key role in maintaining the body’s circadian rhythm. If the phase of this biological clock is disrupted, it affects various parts of the brain, which can cause psychiatric conditions such as depression. >
The possibility of using the digital twin of this circadian clock to predict the symptoms of depression was verified through collaboration with the research team of Professor Srijan Sen of the Michigan Neuroscience Institute and Professor Amy Bohnert of the Department of Psychiatry of the University of Michigan.
The collaborative research team conducted a large-scale prospective cohort study involving approximately 800 shift workers and showed that the circadian rhythm disruption digital biomarker estimated through the technology can predict tomorrow's mood as well as six symptoms, including sleep problems, appetite changes, decreased concentration, and suicidal thoughts, which are representative symptoms of depression.
< Figure 3. The circadian rhythm of hormones such as melatonin regulates various physiological functions and behaviors such as heart rate and activity level. These physiological and behavioral signals can be measured in daily life through wearable devices. In order to estimate the body’s circadian rhythm inversely based on the measured biometric signals, a mathematical algorithm is needed. This algorithm plays a key role in accurately identifying the characteristics of circadian rhythms by extracting hidden physiological patterns from biosignals. >
Professor Dae Wook Kim said, "It is very meaningful to be able to conduct research that provides a clue for ways to apply wearable biometric data using mathematics that have not previously been utilized for actual disease management." He added, "We expect that this research will be able to present continuous and non-invasive mental health monitoring technology. This is expected to present a new paradigm for mental health care. By resolving some of the major problems socially disadvantaged people may face in current treatment practices, they may be able to take more active steps when experiencing symptoms of depression, such as seeking counsel before things get out of hand."
< Figure 4. A mathematical algorithm was devised to circumvent the problems of estimating the phase of the brain's biological clock and sleep stages inversely from the biodata collected by a smartwatch. This algorithm can estimate the degree of daily circadian rhythm disruption, and this estimate can be used as a digital biomarker to predict depression symptoms. >
The results of this study, in which Professor Dae Wook Kim of the Department of Brain and Cognitive Sciences at KAIST participated as the joint first author and corresponding author, were published in the online version of the international academic journal npj Digital Medicine on December 5, 2024. (Paper title: The real-world association between digital markers of circadian disruption and mental health risks) DOI: 10.1038/s41746-024-01348-6
This study was conducted with the support of the KAIST's Research Support Program for New Faculty Members, the US National Science Foundation, the US National Institutes of Health, and the US Army Research Institute MURI Program.
2025.01.20 View 5804 -
KAIST Proposes a New Way to Circumvent a Long-time Frustration in Neural Computing
The human brain begins learning through spontaneous random activities even before it receives sensory information from the external world. The technology developed by the KAIST research team enables much faster and more accurate learning when exposed to actual data by pre-learning random information in a brain-mimicking artificial neural network, and is expected to be a breakthrough in the development of brain-based artificial intelligence and neuromorphic computing technology in the future.
KAIST (President Kwang-Hyung Lee) announced on the 16th of December that Professor Se-Bum Paik 's research team in the Department of Brain Cognitive Sciences solved the weight transport problem*, a long-standing challenge in neural network learning, and through this, explained the principles that enable resource-efficient learning in biological brain neural networks.
*Weight transport problem: This is the biggest obstacle to the development of artificial intelligence that mimics the biological brain. It is the fundamental reason why large-scale memory and computational work are required in the learning of general artificial neural networks, unlike biological brains.
Over the past several decades, the development of artificial intelligence has been based on error backpropagation learning proposed by Geoffery Hinton, who won the Nobel Prize in Physics this year. However, error backpropagation learning was thought to be impossible in biological brains because it requires the unrealistic assumption that individual neurons must know all the connected information across multiple layers in order to calculate the error signal for learning.
< Figure 1. Illustration depicting the method of random noise training and its effects >
This difficult problem, called the weight transport problem, was raised by Francis Crick, who won the Nobel Prize in Physiology or Medicine for the discovery of the structure of DNA, after the error backpropagation learning was proposed by Hinton in 1986. Since then, it has been considered the reason why the operating principles of natural neural networks and artificial neural networks will forever be fundamentally different.
At the borderline of artificial intelligence and neuroscience, researchers including Hinton have continued to attempt to create biologically plausible models that can implement the learning principles of the brain by solving the weight transport problem.
In 2016, a joint research team from Oxford University and DeepMind in the UK first proposed the concept of error backpropagation learning being possible without weight transport, drawing attention from the academic world. However, biologically plausible error backpropagation learning without weight transport was inefficient, with slow learning speeds and low accuracy, making it difficult to apply in reality.
KAIST research team noted that the biological brain begins learning through internal spontaneous random neural activity even before experiencing external sensory experiences. To mimic this, the research team pre-trained a biologically plausible neural network without weight transport with meaningless random information (random noise).
As a result, they showed that the symmetry of the forward and backward neural cell connections of the neural network, which is an essential condition for error backpropagation learning, can be created. In other words, learning without weight transport is possible through random pre-training.
< Figure 2. Illustration depicting the meta-learning effect of random noise training >
The research team revealed that learning random information before learning actual data has the property of meta-learning, which is ‘learning how to learn.’ It was shown that neural networks that pre-learned random noise perform much faster and more accurate learning when exposed to actual data, and can achieve high learning efficiency without weight transport.
< Figure 3. Illustration depicting research on understanding the brain's operating principles through artificial neural networks >
Professor Se-Bum Paik said, “It breaks the conventional understanding of existing machine learning that only data learning is important, and provides a new perspective that focuses on the neuroscience principles of creating appropriate conditions before learning,” and added, “It is significant in that it solves important problems in artificial neural network learning through clues from developmental neuroscience, and at the same time provides insight into the brain’s learning principles through artificial neural network models.”
This study, in which Jeonghwan Cheon, a Master’s candidate of KAIST Department of Brain and Cognitive Sciences participated as the first author and Professor Sang Wan Lee of the same department as a co-author, was presented at the 38th Neural Information Processing Systems (NeurIPS), the world's top artificial intelligence conference, on December 14th in Vancouver, Canada. (Paper title: Pretraining with random noise for fast and robust learning without weight transport)
This study was conducted with the support of the National Research Foundation of Korea's Basic Research Program in Science and Engineering, the Information and Communications Technology Planning and Evaluation Institute's Talent Development Program, and the KAIST Singularity Professor Program.
2024.12.16 View 6001 -
KAIST Unveils New Possibilities for Treating Intractable Brain Tumors
< Photo 1. (From left) Professor Heung Kyu Lee, KAIST Department of Biological Sciences, and Dr. Keun Bon Ku >
Immunotherapy, which enhances the immune system's T cell response to eliminate cancer cells, has emerged as a key approach in cancer treatment. However, in the case of glioblastoma, an aggressive and treatment-resistant brain tumor, numerous clinical trials have failed to confirm their efficacy. Korean researchers have recently analyzed the mechanisms that cause T cell exhaustion, which is characterized by a loss of function or a weakened response following prolonged exposure to antigens in such intractable cancers, identifying key control factors in T cell activation and clarifying the mechanisms that enhance therapeutic effectiveness.
KAIST (represented by President Kwang Hyung Lee) announced on the 6th of November that Professor Heung Kyu Lee’s team from the Department of Biological Sciences, in collaboration with the Korea Research Institute of Chemical Technology (represented by President Young Kuk Lee), has confirmed improved survival rates in a glioblastoma mouse model. By removing the inhibitory Fc gamma receptor (FcγRIIB), the research team was able to restore the responsiveness of cytotoxic T cells to immune checkpoint inhibitors, leading to enhanced anticancer activity.
The research team examined the effect of FcγRIIB, an inhibitory receptor recently found in cytotoxic T cells, on tumor-infiltrating T cells and the therapeutic effectiveness of the anti-PD-1 immune checkpoint inhibitor.
< Figure 1. Study results on improved survival rate due to increased antitumor activity of anti-PD-1 treatment in inhibitory Fc gamma receptor(Fcgr2b) ablation mice with murine glioblastoma. >
Their findings showed that deleting FcγRIIB induced the increase of tumor antigen-specific memory T cells, which helps to suppress exhaustion, enhances stem-like qualities, and reactivates T cell-mediated antitumor immunity, particularly in response to anti-PD-1 treatment. Furthermore, FcγRIIB deletion led to an increase in antigen-specific memory T cells that maintained continuous infiltration into the tumor tissue.
This study presents a new therapeutic target for tumors unresponsive to immune checkpoint inhibitors and demonstrates that combining FcγRIIB inhibition with anti-PD-1 treatment can produce synergistic effects, potentially improving therapeutic outcomes for tumors like glioblastoma, which typically show resistance to anti-PD-1 therapy.
< Figure 2. Overview of the study on the enhanced response to anti-PD-1 therapy for glioblastoma brain tumors upon deletion of the inhibitory Fc gamma receptor (FcγRIIB) in tumor microenvironment. When the inhibitory Fc gamma receptor (FcγRIIB) of cytotoxic T cells is deleted, an increase in tumor-specific memory T cells (Ttsms) was observed. In addition, this T cell subset is identified as originating from the tumor-draining lymph nodes(TdLNs) and leads to persistent infiltration into the tumor tissue. Anti-PD-1 therapy leads to an increased anti-tumor immune response via Ttsms, which is confirmed by increased tumor cell toxicity and increased cell division and decreased cell de-migration indices. Ultimately, the increased cytotoxic T cell immune response leads to an increase in the survival rate of glioblastoma. >
Professor Heung Kyu Lee explained, "This study offers a way to overcome clinical failures in treating brain tumors with immune checkpoint therapy and opens possibilities for broader applications to other intractable cancers. It also highlights the potential of utilizing cytotoxic T cells for tumor cell therapy."
The study, led by Dr. Keun Bon Ku of KAIST (currently a senior researcher at the Korea Research Institute of Chemical Technology's Center for Infectious Disease Diagnosis and Prevention), along with Chae Won Kim, Yumin Kim, Byeong Hoon Kang, Jeongwoo La, In Kang, Won Hyung Park, Stephen Ahn, and Sung Ki Lee, was published online on October 26 in the Journal for ImmunoTherapy of Cancer, an international journal in tumor immunology and therapy from the Society for Immunotherapy of Cancer. (Paper title: “Inhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma,” http://dx.doi.org/10.1136/jitc-2024-009449).
This research received support from the National Research Foundation of Korea, the Bio & Medical Technology Development Program, and the Samsung Science & Technology Foundation.
2024.11.15 View 4397 -
Unraveling Mitochondrial DNA Mutations in Human Cells
Throughout our lifetime, cells accumulate DNA mutations, which contribute to genetic diversity, or “mosaicism”, among cells. These genomic mutations are pivotal for the aging process and the onset of various diseases, including cancer. Mitochondria, essential cellular organelles involved in energy metabolism and apoptosis, possess their own DNA, which are susceptible to mutations. However, studies on mtDNA mutations and mosaicism have been limited due to a variety of technical challenges.
Genomic scientists from KAIST have revealed the genetic mosaicism characterized by variations in mitochondrial DNA (mtDNA) across normal human cells. This study provides fundamental insights into understanding human aging and disease onset mechanisms.
The study, “Mitochondrial DNA mosaicism in normal human somatic cells,” was published in Nature Genetics on July 22. It was led by graduate student Jisong An under the supervision of Professor Young Seok Ju from the Graduate School of Medical Science and Engineering.
Researchers from Seoul National University College of Medicine, Yonsei University College of Medicine, Korea University College of Medicine, Washington University School of Medicine National Cancer Center, Seoul National University Hospital, Gangnam Severance Hospital and KAIST faculty startup company Inocras Inc. also participated in this study.
< Figure 1. a. Flow of experiment. b. Schematic diagram illustrating the origin and dynamics of mtDNA alterations across a lifetime. >
The study involved a bioinformatic analysis of whole-genome sequences from 2,096 single cells obtained from normal human colorectal epithelial tissue, fibroblasts, and blood collected from 31 individuals. The study highlights an average of three significant mtDNA differences between cells, with approximately 6% of these variations confirmed to be inherited as heteroplasmy from the mother.
Moreover, mutations significantly increased during tumorigenesis, with some mutations contributing to instability in mitochondrial RNA. Based on these findings, the study illustrates a computational model that comprehensively elucidates the evolution of mitochondria from embryonic development to aging and tumorigenesis.
This study systematically reveals the mechanisms behind mitochondrial DNA mosaicism in normal human cells, establishing a crucial foundation for understanding the impact of mtDNA on aging and disease onset.
Professor Ju remarked, “By systematically utilizing whole-genome big data, we can illuminate previously unknown phenomena in life sciences.” He emphasized the significance of the study, adding, “For the first time, we have established a method to systematically understand mitochondrial DNA changes occurring during human embryonic development, aging, and cancer development.”
This work was supported by the National Research Foundation of Korea and the Suh Kyungbae Foundation.
2024.07.24 View 4747 -
KAIST begins full-scale cooperation with Taiwan’s Formosa Group
< (From left) Senior Vice President for Planning and Budget Kyung-Soo Kim, and Professor Minee Choi of the Department of Brain and Cognitive Sciences of KAIST along with Chairman of Formosa Group Sandy Wang and KAIST President Kwang-Hyung Lee, and Dean Daesoo Kim of KAIST College of Life Science and Bioengineering >
KAIST is pursuing cooperation in the fields of advanced biotechnology and eco-friendly energy with Formosa Plastics Group, one of Taiwan's three largest companies.
To this end, Chairman Sandy Wang, a member of Formosa Group's standing committee and leader of the group's bio and eco-friendly energy sector, will visit KAIST on the 13th of this month. This is the first time that the owner of Formosa Group has made an official visit to KAIST.
Cooperation between the two institutions began last March when our university signed a memorandum of understanding on comprehensive exchange and cooperation with Ming Chi University of Science and Technology (明志科技大學), Chang Gung University(長庚大學), and Chang Gung Memorial Hospital(長庚記念醫院), three of many institutions established and supported by Formosa Group.
Based on this, Chairman Sandy Wang, who visits our university to promote more exchanges and cooperation, talked about ‘the education of children and corporate social return and practice of his father, Chairman Yung-Ching Wang,’ through a special lecture for the school leadership as a part of the Monthly Lecture on KAIST’s Leadership Innovation Day.
She then visited KAIST's research and engineering facilities related to Taiwan's future industries, such as advanced biotechnology and eco-friendly energy, and discussed global industry-academic cooperation plans. In the future, the two organizations plan to appoint adjunct professors and promote practical global cooperation, including joint student guidance and research cooperation. We plan to pursue effective mid- to long-term cooperation, such as conducting battery application research with the KAIST Next-Generation ESS Research Center and opening a graduate program specialized in stem cell and gene editing technology in connection with Chang Gung University and Chang Gung Memorial Hospital. The newly established cooperative relationship will also promote Formosa Group's investment and cooperation with KAIST's outstanding venture companies related to bio and eco-friendly energy to lay the foundation for innovative industrial cooperation between Taiwan and Korea.
President Kwang-Hyung Lee said, “The Formosa Group has a global network, so we regard it to be a key partner that will position KAIST’s bio and engineering technology in the global stages.” He also said, “With Chairman Sandy Wang’s visit, Taiwan is emerging as a global economic powerhouse,” and added, “We expect to continue our close cooperative relationship with the company.”
Formosa Group is a company founded by the late Chairman Yung-Ching Wang, the father of Chairman Sandy Wang. As the world's No. 1 plastic PVC producer, it is leading the core industries of Taiwan's economy, including semiconductors, steel, heavy industry, bio, and batteries. Chairman Yung-Ching Wang was respected by the Taiwanese people by setting an example of returning his wealth to society under the belief that the companies and assets he built ‘belonged to the people.’ Chang Gung University, Chang Gung Memorial Hospital, and Ming Chi University of Technology, which are pursuing cooperation with our university, were also established as part of the social contribution promoted by Chairman Yung-Ching Wang and are receiving financial support from Formosa Group.
2024.05.09 View 5601